TY - JOUR
T1 - Fertility-sparing surgery of malignant transformation arising from mature cystic teratoma of the ovary
AU - Yoshikawa, Nobuhisa
AU - Teshigawara, Toshiya
AU - Ikeda, Yoshiki
AU - Nishino, Kimihiro
AU - Sakata, Jun
AU - Utsumi, Fumi
AU - Niimi, Kaoru
AU - Sekiya, Ryuichiro
AU - Suzuki, Shiro
AU - Kawai, Michiyasu
AU - Shibata, Kiyosumi
AU - Kikkawa, Fumitaka
AU - Kajiyama, Hiroaki
N1 - Publisher Copyright:
© Yoshikawa et al.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Background: The purpose of this study was to evaluate the long-term clinical outcome of young women with malignant transformation arising from mature cystic teratoma of the ovary (MT-MCT) by comparing radical surgery and fertility-sparing surgery (FSS). Patients and methods: All patients treated with radical surgery or FSS for MT-MCT in multiple institutions were registered in this analysis. Univariate and multivariate analyses were performed to evaluate clinical outcome, including overall survival (OS) and disease-free survival (DFS). Results: From 1986 to 2016, 62 patients with MT-MCT were treated in our group. The median follow-up period was 38.0 (2.0-227.9) months, and the median age was 54 (17-82) years old. Multivariate analysis revealed that only advanced stage was significantly correlated with poorer prognosis of patients [hazard ratio (HR) for death: 6.58, 95% confidence interval (CI): 1.82-24.78, P = 0.0048; HR for recurrence: 5.59, 95% CI: 1.52-21.83, P = 0.01]. Of a total of 13 women with stage I-II disease at less than 45 years old, 7 were treated with FSS, and there was no recurrence except for in one woman with stage II MT-MCT. There was no significant difference in long-term oncological outcome between radical surgery and FSS. Conclusion: FSS may be indicated for patients with stage I MT-MCT, who hope to preserve fertility, as no relapse was found after FSS.
AB - Background: The purpose of this study was to evaluate the long-term clinical outcome of young women with malignant transformation arising from mature cystic teratoma of the ovary (MT-MCT) by comparing radical surgery and fertility-sparing surgery (FSS). Patients and methods: All patients treated with radical surgery or FSS for MT-MCT in multiple institutions were registered in this analysis. Univariate and multivariate analyses were performed to evaluate clinical outcome, including overall survival (OS) and disease-free survival (DFS). Results: From 1986 to 2016, 62 patients with MT-MCT were treated in our group. The median follow-up period was 38.0 (2.0-227.9) months, and the median age was 54 (17-82) years old. Multivariate analysis revealed that only advanced stage was significantly correlated with poorer prognosis of patients [hazard ratio (HR) for death: 6.58, 95% confidence interval (CI): 1.82-24.78, P = 0.0048; HR for recurrence: 5.59, 95% CI: 1.52-21.83, P = 0.01]. Of a total of 13 women with stage I-II disease at less than 45 years old, 7 were treated with FSS, and there was no recurrence except for in one woman with stage II MT-MCT. There was no significant difference in long-term oncological outcome between radical surgery and FSS. Conclusion: FSS may be indicated for patients with stage I MT-MCT, who hope to preserve fertility, as no relapse was found after FSS.
UR - https://www.scopus.com/pages/publications/85048241573
UR - https://www.scopus.com/pages/publications/85048241573#tab=citedBy
U2 - 10.18632/oncotarget.25548
DO - 10.18632/oncotarget.25548
M3 - Article
C2 - 29938006
AN - SCOPUS:85048241573
SN - 1949-2553
VL - 9
SP - 27564
EP - 27573
JO - Oncotarget
JF - Oncotarget
IS - 44
ER -